Proactive Investors - Run By Investors For Investors

PreveCeutical Medical unveils promising findings from non-addictive analgesics program

The firm is developing therapies using organic and nature identical products
PreveCeutical Medical unveils promising findings from non-addictive analgesics program
The company currently has five research and development programs on the go

Health sciences group PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) said it had completed a study of peptides to develop as non-addictive painkillers, with promising results.

The firm is developing therapies using organic and nature identical products.

READ: PreveCeutical Medical reports converting acid phytocannabinoids to neutral form

One of its programs is for non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone.

Preveceutical said that via a meticulous process it had now identified five novel peptide constructs, which preferentially target the receptor subtype which is of interest to the company and is purported to avoid addictive and tolerance-inducing side effects.

This subset of peptides has demonstrated potency, in a well-accepted functional dose response assay, that is on par with clinically available agents, such as morphine, the company added.

Chief research officer Dr Harendra Parekh told investors: "We are very pleased with this promising development, as a result of numerous iterations between our peptide design and cell-based screening efforts, we have now yielded a number of constructs which discriminate between the key pain receptors in the body, and importantly, avoid activation of those purported to lead to dependence."

Preveceutical shares in Toronto were unchanged at $0.06 each.

Contact Giles at [email protected]

Follow him on Twitter @Gile74

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use